InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,230.00
(
-0.15%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,216.19
(
0.20%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 3030

Thursday, 05/24/2007 1:56:58 AM

Thursday, May 24, 2007 1:56:58 AM

Post# of 19309
Maxygen MAXY-Seven (rFVIIa) update:

Now that Roche has dropped out of the development program for MAXY-Seven (#msg-17854630), MAXY will no longer pursue acute bleeding conditions as an initial program goal. Instead, MAXY says it will focus on hemophilia and will file an IND to begin phase-1 in 1H08.

MAXY’s stated reason for dropping the acute settings from the development program is that the regulatory path for these indications is unclear. (Roche had previously cited the lack of a large-animal model for acute bleeding conditions as a significant impediment.)

Despite the talk of a strong commitment to a scaled-back MAXY-Seven program, I foresee the program’s getting squeezed by MAXY’s budgetary constraints and proceeding slowly, if at all. Moreover, for the reasons mentioned in #msg-17854630, I question the need for an “enhanced” rFVIIa product. Evidently, Roche does too.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up